Uterine sarcomas are malignant tumors with poor prognosis. The purpose is to clarify the epidemiological, diagnostic difficulties and therapeutic modalities and prognosis of uterine sarcomas. Twelve cases of uterine sarcomas supported the National Institute of Oncology (2008-2011) were analyzed. The average age is 43.75 years. Patients viewed had the clinical triad of bleeding, pain and / or pelvic mass. On the para-clinical, seven patients had an inconclusive ultrasound, however the scan was performed in all our patients showing a pelvic mass. The realization of the biopsy endometrial curettage led to the diagnosis. All patients underwent a hysterectomy associated with lymph node dissection in cases with carcinomatous component. Histological analysis of surgical specimens objectified 06 carcinosarcomas, 03 leiomyosarcoma, 02 endometrial stromal sarcoma and an adenosarcoma. In our study in discordance with the literature, the mixed mesenchymal tumors (carcinosarcoma and adenosarcoma) are the most common histological type 58.33% followed by pur sarcoma (sarcoma and endometrial stromal leiomyosarcoma) with a frequency of 41.67%. The average age of patients (43.75 years) is consistent with the literature. The classic clinical triad, reported by most authors, was found in the majority of patients. MRI and PET scan are the most successful exams. The diagnosis rests on hysterectomy’s piece. For treatment, surgery with hysterectomy and adnexectomy with or without lymph node dissection followed by external radiation therapy is the gold standard. Indeed, uterine sarcomas are malignant tumors with poor prognosis whose diagnosis is primarily postoperative. Surgery with radiation therapy is the gold standard. Hope rests on new drugs that are being tested.